An interventional study of Specific Exercise Therapy in Breast Cancer, sponsored by Al Hayah University In Cairo. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-09.
Sponsored by Al Hayah University In Cairo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Breast Neoplasms with a site in Egypt — 58 open to participants now, 68 under way, 5 of them phase 3. Breast Neoplasms · Egypt.
Among the 248 studies in Breast Neoplasms with a site in Egypt, this one is the 37th largest by planned enrollment of the 183 interventional ones that give a count, is one of 25 that started in 2025, is one of 85 with no phase, reaches primary completion later than 43 of the 67 other live ones, and was the 195th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →58 of the 248 studies in Breast Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 65–75 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
Adly A Adam · Sites in Egypt
Ages 40–50 · Women only
Sohag University · Sites in Egypt
Ages 18–80
Alexandria University · Sites in Egypt
Ages 18–70 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 46 · Phase 3 47 · Phase 4 11
First in 1997; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 70 across the 183 interventional studies, 100 across the 63 observational. Of the 131 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 248 have an industry lead sponsor. The 10 most frequent:
Al Hayah University In Cairo is the lead sponsor of 16 studies on the registry; 12 are open to participants now.
Al Hayah University In Cairo has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Breast Neoplasms with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596122Abdelrahman MahmoudVitamin D Supplementation in Breast Cancer Patients | 2026-11-30 |
| NCT07095569National Cancer Institute, EgyptShoulder Denervation for Post Mastectomy Irradiation Shoulder Pain | 2026-12-01 |
| NCT07650305National Cancer Institute, EgyptBilevel Erector Spinae Plane Block Versus Pectoserratus Block for Analgesia in Modified Radical Mastectomy | 2026-12-01 |
| NCT07894133Adly A AdamGait Parameters in Breast Cancer Receiving Chemotherapy Patients | 2026-12-01 |
| NCT01101425European Organisation for Research and Treatment of Cancer - EORTCMale Breast Cancer: Understanding the Biology for Improved Patient Care | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 248 studies in Breast Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, parallel-group randomized controlled trial (RCT) will compare two timings for initiating specific exercise therapy after breast cancer surgery. The study tests whether early initiation (within the first postoperative week) versus delayed initiation (at 3 weeks postoperative) results in superior upper limb function at 6 months as measured by the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire. Secondary outcomes include pain intensity (Visual Analog Scale, VAS) and wound-related complications such as drainage time and hematoma incidence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, participants will initiate specific exercise therapy within the first postoperative week. They will receive 40-minute supervised sessions twice weekly for 8 weeks, with a transition to a prescribed home-based maintenance program for an additional 4 months.
Behavioral: Specific Exercise Therapy
Participants in this group will begin the same specific exercise therapy protocol at 3 weeks postoperative. Otherwise, the intervention is identical to that provided to the Early Therapy group.
Behavioral: Specific Exercise Therapy
The exercise protocol includes mobilisation and stretching with 40-minute sessions twice weekly for 8 weeks post-initiation, transitioning to a home-based maintenance phase for 4 months. All sessions will be supervised by certified physiotherapists.
Upper Limb Function (DASH Questionnaire)
The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a validated measure of upper limb function. The questionnaire is scored on a continuous scale ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe disability. Lower scores indicate better upper limb function.
Time frame: Assessed preoperatively (baseline) and at 6 months postoperative.
Pain Intensity (Visual Analog Scale - VAS)
A 0-100 VAS will measure patient-reported pain levels, where 0 signifies no pain and 100 the worst pain imaginable.
Time frame: Assessed at baseline and at 1, 3, and 6 months postoperative.
Wound-Related Complications - Drainage Time (Days)
The duration of wound drainage will be recorded in days. Longer drainage time may indicate wound complications.
Time frame: Monitored during the immediate postoperative period up to 3 months.
Wound-Related Complications - Incidence of Hematoma
The occurrence of hematoma will be documented as a binary outcome (presence or absence) for each patient. The incidence will be calculated as the proportion of patients developing hematoma during the monitoring period.
Time frame: Monitored during the immediate postoperative period up to 3 months.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Nov 2026, 19 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al Hayah University In Cairo